NEW YORK (GenomeWeb) – Biodesix said today that it has received positive coverage decisions for its Veristrat test from Humana, Medical Mutual of Ohio, and PreferredOne.

Veristrat, Biodesix's flagship product, is a blood-based proteomic test for assessing patient prognosis and predicting response to drug treatment in advanced NSCLC.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.